Journal of the American College of Cardiology
Authors: Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Thanh Hai MT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ
BMJ quality & safety
Authors: Dhaliwal G, Shojania KG
Sleep & breathing = Schlaf & Atmung
Authors: Kundel V, Trivieri MG, Karakatsanis NA, Robson PM, Mani V, Kizer JR, Kaplan R, Fayad Z, Shah N
Breast cancer research and treatment
Authors: Rice MS, Tamimi RM, Bertrand KA, Scott CG, Jensen MR, Norman AD, Visscher DW, Chen YY, Brandt KR, Couch FJ, Shepherd JA, Fan B, Wu FF, Ma L, Collins LC, Cummings SR, Kerlikowske K, Vachon CM
American journal of kidney diseases : the official journal of the National Kidney Foundation
Authors: Ku E, Vittinghoff E, Jacobs DR, Lewis CE, Allen NB, Bibbins-Domingo K, Shlipak M, Kramer H, Peralta CA
Nutrition, metabolism, and cardiovascular diseases : NMCD
Authors: Garg PK, Biggs ML, Kaplan R, Kizer JR, Heckbert SR, Mukamal KJ
Journal of the American Academy of Dermatology | Volume 79 of Issue 3
Authors: Yoon J, Phibbs CS, Chow A, Weinstock MA, Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial Group
BACKGROUND
It is unknown whether treatment costs for keratinocyte carcinoma (KC) and actinic keratosis (AK) can be lowered by spending more on chemoprevention.
OBJECTIVE
To examine the impact of 1-course treatment with topical fluorouracil (5-FU) on the face and ears on KC and AK treatment costs over 3 years.
METHODS
The Veterans Affairs Keratinocyte Carcinoma Chemoprevention trial compared the efficacy of topical 5-FU 5% with that of vehicle control cream for reducing KC risk. Trial data and administrative data on costs and utilization were analyzed to measure postrandomization encounters and treatment costs for KC and AK care. Adjusted models were used to test for statistically significant differences between treatment arms for number of treatment encounters and costs.
RESULTS
One year after randomization, the control arm had a higher mean number of treatment encounters for squamous cell carcinoma (0.04) than the intervention arm (0.01) (P < .01). At 1 year, the intervention arm had lower treatment and dermatologic costs: $2106 (standard deviation, $2079) compared with $2444 (standard deviation, $2716) for the control patients (P = .02). After 3 years, the intervention arm incurred a cost of $771 less per patient.
LIMITATIONS
Care not provided or paid for by the Department of Veterans Affairs was not included. Results may not be generalizable to other payers.
CONCLUSION
We found significant cost savings for patients treated with 5-FU.
View on PubMed
The journals of gerontology. Series A, Biological sciences and medical sciences
Authors: Leng Y, Stone K, Ancoli-Israel S, Covinsky K, Yaffe K
The journals of gerontology. Series A, Biological sciences and medical sciences
Authors: Leng Y, Stone K, Ancoli-Israel S, Covinsky K, Yaffe K
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Authors: Inker LA, Levey AS, Tighiouart H, Shafi T, Eckfeldt JH, Johnson C, Okparavero A, Post WS, Coresh J, Shlipak MG
